2. Academic Validation
  3. Immunotherapy in multiple myeloma

Immunotherapy in multiple myeloma

  • Cancer Treat Res Commun. 2021;29:100468. doi: 10.1016/j.ctarc.2021.100468.
Yamna Jadoon 1,  Mustaqeem A Siddiqui 2
Affiliations

Affiliations

  • 1 Division of Hematology, Mayo Clinic, Rochester MN, United States of America.
  • 2 Division of Hematology, Mayo Clinic, Rochester MN, United States of America; Division of Oncology and Hematology, Sheikh Shakhbout Medical City, Abu Dhabi, UAE. Electronic address: siddiqui.mustaqeem@mayo.edu.
PMID: 34653747 DOI: 10.1016/j.ctarc.2021.100468
Abstract

Despite available therapies, Multiple Myeloma (MM) remains an incurable hematologic malignancy. Over the past three decades, there have been tremendous developments in therapeutic options for MM. In regards to immunotherapy, Daratumumab was the first monoclonal antibody to receive FDA approval for multiple myeloma. Since then, Other monoclonal Antibodies such as elotuzumab and isatuximab have received FDA approval. Many clinical trials are underway investigating the efficacy of newer immunotherapies. This review summarizes recently presented and/or published data regarding this growing field, specifically regarding monoclonal Antibodies, antibody-drug conjugates, bispecific Antibodies, and trispecific Antibodies.

Keywords

Antibody drug conjugates; Bispecific antibodies; Immunotherapy; Monoclonal antibodies; Multiple myeloma; Trispecific antibodies.

Figures
Products